Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results von Lesokhin, Alexander M., Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J., Miles Prince, H., Niesvizky, Ruben, Rodrίguez-Otero, Paula, Martinez-Lopez, Joaquin, Koehne, Guenther, Touzeau, Cyrille, Jethava, Yogesh, Quach, Hang, Depaus, Julien, Yokoyama, Hisayuki, Gabayan, Afshin Eli, Stevens, Don A., Nooka, Ajay K., Manier, Salomon, Raje, Noopur, Iida, Shinsuke, Raab, Marc-Steffen, Searle, Emma, Leip, Eric, Sullivan, Sharon T., Conte, Umberto, Elmeliegy, Mohamed, Czibere, Akos, Viqueira, Andrea, Mohty, Mohamad

Volltext

Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma von Jagannath, Sundar, Durie, Brian G. M., Wolf, Jeffrey Lee, Camacho, Elber S., Irwin, David, Lutzky, Jose, McKinley, Marti, Potts, Phyllis, Gabayan, Afshin Eli, Mazumder, Amitabha, Crowley, John, Vescio, Robert

Volltext

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma von Jagannath, Sundar, Durie, Brian G. M., Wolf, Jeffrey, Camacho, Elber, Irwin, David, Lutzky, Jose, McKinley, Marti, Gabayan, Eli, Mazumder, Amitabha, Schenkein, David, Crowley, John

Volltext

Abstract PR013: First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer von Mamdani, Hirva, Chiappori, Alberto, Bazhenova, Lyudmila, Spira, Alexander, Iams, Wade, Barve, Minal, Tolcher, Anthony W, Gabayan, Eli, Vandross, Andrae, Huynh, Annie, Cohen-Arazi, Yael, Albaugh, Zachary, Gullbo, Joachim, Zabludoff, Sonya

Volltext

Magnetismm-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma von Lesokhin, Alexander, Iida, Shinsuke, Stevens, Don, Gabayan, Afshin Eli, Ma, Wei Dong, Sullivan, Sharon, Raab, Marc-Steffen

Volltext

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab‐Paclitaxel and Gemcitabine in Advanced Solid Tumors von Beatty, Gregory L, Shahda, Safi, Beck, Thaddeus, Uppal, Nikhil, Cohen, Steven J, Donehower, Ross, Gabayan, Afshin Eli, Assad, Albert, Switzky, Julie, Zhen, Huiling, Von Hoff, Daniel D

Volltext

Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly admini... von Mohty, Mohamad, Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J., Prince, H. Miles, Niesvizky, Ruben, Rodríguez-Otero, Paula, Martinez-Lopez, Joaquin, Koehne, Guenther, Jethava, Yogesh, Gabayan, A. Eli, Stevens, Don A., Nooka, Ajay K., Raje, Noopur S., Iida, Shinsuke, Leip, Eric, Conte, Umberto, Czibere, Akos Gabor, Viqueira, Andrea, Lesokhin, Alexander M.

Volltext

TRUST-II: A global phase II study for taletrectinib in ROS1 fusion–positive lung cancer and other solid tumors von Nagasaka, Misako, Sugawara, Shunichi, Choi, Chang-Min, Okamoto, Tatsuro, Yanagitani, Noriko, Nosaki, Kaname, Takahashi, Toshiaki, Fujiwara, Yutaka, Hayashi, Hidetoshi, Khoury, John, Nieva, Jorge J., Gabayan, A. Eli, Raez, Luis E., Chen, Hongbin, Dimou, Anastasios, Pennell, Nathan A., Liu, Geoffrey, Ou, Sai-Hong Ignatius, Seto, Takashi, Ohe, Yuichiro

Volltext

PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors von Vaena, Daniel A., Chaves, Jorge, Vogelzang, Nicholas J., Matrana, Marc Ryan, Gabayan, A. Eli, Riese, Matthew John, Cho, Daniel C., Tagliaferri, Mary Ann, Zalevsky, Jonathan, Xie, Sunny, Hoch, Ute, RIZWAN, AHSAN NAQI, Aung, Sandra, Imperiale, Michael, Schwarz, James K.

Volltext

A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC) von Beatty, Gregory Lawrence, Shahda, Safi, Beck, J. Thaddeus, Uppal, Nikhil Premparkash, Cohen, Steven J., Donehower, Ross C., Gabayan, A. Eli, Assad, Albert, Switzky, Julie C., Zhen, Huiling, Von Hoff, Daniel D.

Volltext

A Phase 2 Study of Bortezomib as First-Line Therapy in Patients with Multiple Myeloma von Jagannath, Sundar, Brian, Durie, Wolf, Jeffrey L., Camacho, Elber, Irwin, David, Lutzky, Jose, McKinley, Marti, Gabayan, Eli, Mazumder, Amitabha, Crowley, John, Schenkein, David

Volltext

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma von Jagannath, Sundar, Durie, Brian G.M., Wolf, Jeffrey Lee, Camacho, Elber S., Irwin, David, Lutzky, Jose, McKinley, Marti, Gabayan, Afshin Eli, Mazumder, Amitabha, Crowley, John, Vescio, Robert

Volltext